The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer;Znaczenie ekspresji antygenu Ki-67 ocenianej metoda̧ mikromacierzy tkankowych dla rokowania u chorych z gruczolakorakiem endometrialnym endometrium

Ginekologia Polska

Volumn 84, Issue 6, 2013, Pages 444-449

  Gottwald, Leszek ^a   Kubiak, Robert ^a   Sȩk, Piotr ^a   Piekarski, Janusz ^a   Szwalski, Jaroslaw ^b   Pasz Walczak, Grazyna ^a   Spych, Michal ^a   Suzin, Jacek ^c   Tyliński, Wieslaw ^c   Jeziorski, Arkadiusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Olympus Consilio Sp z OO w odzi   (Poland)

^c Klinika Kardiologii Interwencyjnej i Kardiodiagnostyki   (Poland)

Author keywords

Endometrioid endometrial cancer; Ki 67 antigen; Prognosis; Tissue microarray

Indexed keywords

EID: 84881335760     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1602     Document Type: Article

References (35)

1. Zaktad Epidemiologii i Prewencji Nowotworow Centrum Onkologii - Instytut w Warszawie. Krajowa baza danych nowotworowych. http://www.onkologia.org.pl
2. Benedet J, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines for gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J GynaecolObstet. 2000, 70, 209-262.
3. Silverberg S, Kurman R, Nogales F, et al. Epithelial tumours and related lesions. In: World Health Organization Classification of tumors. Pathology and genetics of tumours of the breast and female genital organs. Eds. Tavassoli F, Devilee P. Lyon: IARC Press, 2003, 221-232.
4. Steinbakk A, Gudlaugsson E, Aasprong O, et al. Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am J Obstet Gynecol. 2011, 204, 357.e1-12.
5. Jeon Y, Part I, Kim Y et al. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett. 2006, 239, 198-204.
6. Ikawa S, Sano T, Furumoto H, et al. Multidirectional differentiation of endometrial carcinoma with special reference to tumor aggressiveness evaluated by Ki-67 expression. Gynecol Oncol. 1999, 72, 323-330.
7. Markova I, Duskova M, Lubusky M, et al. Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer. 2010, 20, 576-582.
8. Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007, 43, 2434-2444.
9. Stoian S, Simionescu C, Margaritescu C, et al. Endometrial carcinomas: correlation between ER PR Ki67 status and histopathological prognostic parameters. Rom J Morphol Embryol. 2011, 52, 631-636.
10. Chakravarty D, Gupta N, Goda J, et al. Steroid receptors HER2/neu and Ki 67 in endometrioid type of endometrial carcinoma: correlation with conventional histomorphological features of prognosis. Acta Histochem. 2010, 112, 355-363.
11. Steiner E, Eicher O, Sagemuller J, et al. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer. 2003, 13, 197-203.
12. Schimp V, Ali-Fehmi R, Solomon L, et al. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level?. Gynecol Oncol. 2006, 102, 440-446.
13. Cattoretti G, Becker M, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave processed formalin-fixed paraffin sections. J Pathol. 1992, 168, 357-363.
14. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984, 133, 1710-1715.
15. Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecol Oncol. 2004, 92, 175-179.
16. Kȩdzia W, Rutkowski R, Jankowska A. [i wsp.]. Markery proliferacji oraz parametry morfo immunologiczne w ocenie czynnikow rokowniczych w rakach btony sluzowej macicy. Ginekol Pol 1997, 68, 199-205.
17. Oreskovic S, Babic D, Kalafatic D, et al. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol. 2004, 93, 34-40.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4, 844-847.
19. Cimbaluk D, Rotmensch J, Scudiere J, et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007, 105, 138-144.
20. Hassan S, Ferrario C, Mamo A, et al. Tissue microarrays: emerging standard for biomarker validation. CurrOpin Biotechnol 2008, 19, 19-25.
21. Huang G, Arend R, Li M, et al. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. Am J Obstet Gynecol. 2009, 200, 457.e1-5.
22. Jongen V, Briet J, de Jong R, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009, 112, 537-542.
23. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet. 2009, 105, 103-104.
24. Dahmoun M, Boman K, Cajander S, Bockstrom T. Intratumoral effects of medroxyprogesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2004, 92, 116-126.
25. Engelsen I, Akslen L, Salvesen H. Biologic markers in endometrial cancer treatment. APMIS. 2009, 117, 693-707.
26. Geisler J, Geisler H, Miller G, et al. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol. 1999, 75, 432-436.
27. Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand. 2004, 83, 1085-1088.
28. Yamauchi N, Sakamuto A, Oozaki H, et al. Immunohistochemical analysis of endometria adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol. 1996, 15, 202-208.
29. Mariani A, Sebo T, Katzmann J, et al. Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol. 2005, 96, 594-600.
30. Geisler J, Wiemann M, Zhou Z, et al. Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Gynecol Oncol. 1996, 61, 373-377.
31. Stefansson I, Salvesen H, Immervoll H, et al. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 2004, 44, 472-479.
32. Gottwald L, Sȩk P, Kubiak R, [i wsp.]. Efektywnosc zastosowania techniki mikromacierzy tkankowych do oceny ekspresji receptorow estrogenowych i progesteronowych w gruczolakoraku endometrialnym endometrium - doniesienie wstȩpne. Ginekol Pol. 2012, 83, 342-346.
33. Gottwald L, Sȩk P, Piekarski J, et al. Construction of a tissue microarray with 2 mm-size cores in endometrioid endometrial cancer - factors affecting quality of the recipient block. Biotech Histochem. 2012, 87, 512-518.
34. Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract. 2007, 203, 169-177.
35. Gulmann C, O'Grady A. Tissue microarrays: an overview. CurrDiagn Pathol. 2003, 9, 149-154.